dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient. There are some cases, although no disease remission was found on imaging,pathological complete response (pCR) was confirmed after surgery. Meanwhile,previous studies have shown that dynamic changes in ctDNA can help assess immunotherapy efficacy. Therefore, we propose to conduct a multicenter, prospective, observational clinical study to explore the efficacy prediction and monitoring value of ctDNA in immunotherapy for advanced or locally advanced dMMR/MSI-H colorectal cancer.
None
None
Colorectal cancer patients with MSI-H/dMMR who are expected to receive / receiving immunotherapy
Cohort
Prospective
Not listed
Correlation of ctDNA changes with pCR rate and the duration of cCR
Correlation of ctDNA changes with rate of pathological complete response or the duration of clinical complete response
Correlation of ctDNA changes with 2 years PFS
Correlation of ctDNA changes with 2 years of progression-free survival after recived immunotherapy
Click on the lead sponsor to view all of their trials.
